|
|
|
12.06.25 - 21:48
|
Maria Ansari, MD, FACC, named to Modern Healthcare′s list of 50 Most Influential Clinical Executives (PR Newswire)
|
|
|
Co-CEO of The Permanente Federation and leader of multiple Permanente Medical Groups at Kaiser Permanente, recognized for advancing AI technology, improving care access, and advocating for value-based care measures OAKLAND, Calif., June 12, 2025 /PRNewswire/ -- Maria Ansari, MD, FACC,......
|
|
|
09.06.25 - 19:39
|
The Inner Circle acknowledges, Vijay S. Iyer, MD, Ph.D, FACC as a Pinnacle Lifetime Member (PR Newswire)
|
|
|
EAST AMHERST, N.Y., June 9, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Vijay S. Iyer, MD, Ph.D, FACC is acknowledged as a Pinnacle Lifetime Member for his contributions to Complex Cardiac and Structural Interventions. Dr. Vijay S. Iyer, MD, Ph.D., FACC, is a......
|
|
|
|
|
22.05.25 - 09:18
|
wikifolio-Trader Alexander Mey (von Rubel): "Wo die Innovation gelebt, gefahren und umgesetzt wird? In Asien!" - SFC und Elmos (BRN)
|
|
|
"Eine breite Korrektur ist ausgeblieben. In der zweiten Reihe bleibt die Emotion auf der Strecke. Der Chartverlauf ist relativ uninspiriert." wikifolio-Trader Alexander Mey alias von Rubel über sein wikifolio TecDachTopPic ( https://www.wikifolio.com/de/de/w/wftedatopi#portfolio ) mit etwas über 30 % Cash und derzeit 9 Werten: Wacker Neuson, ELMOS Semiconductor ("Elmos geht es gut"), OHB, AT&S, Bechtle, SFC Energy, Siltronic, FACC und Nagarro. Zur Automobilbranche meint Mey: "In Asien wird die Innovation gelebt, gefahren und umgesetzt. In Europa haben wir eine falsche Reflexion." Chancen zum Nachkauf bei der "Roten Laterne" Siltronic? "If you are in trouble: double
ich aber warte lieber auf eine Bestätigung beim Umsatz, möchte eine Erholung abwarten. Leider ist die Halbleiterbranche unter Druck."...
|
|
|
20.05.25 - 14:03
|
Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Charmi Turner as senior vice president, people & culture. Charmi is an experienced life sciences industry human resources executive who brings deep expertise in leadership development and organizational alignment to Marea Therapeutics.
“We are thrilled to welcome Charmi to our senior leadership team,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “Charmi will lead the growth of our talent, cultivate our successful culture, and build leadership within the organization, championing Marea's values and the strength of its people. Charmi's appointment comes at a very exciting time of growth for Marea, as our lead program, MAR001 enters Phase 2b clinical development for cardiovascular disease and MAR002 ...
|
|
|
|
|
08.05.25 - 14:06
|
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
|
|
|
Leadership appointment strengthens strategic and development capabilities
FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin
Collaboration Agreement with Abbott (NYSE: ABT) validates the need for new anticoagulation options
PONTE VEDRA, Fla.--(BUSINESS WIRE)--$CVKD #CadrenalTherapeutics--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin.
“In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024,” said Quang X. Pham, Chairman & CEO. “The appointment of James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer positions us for success in reviewing potential assets to add to our portfolio and designing and executing our clinical program for tec...
|
|
|
|
|
|
|
08.04.25 - 22:18
|
FACC Aktie: Capital Markets Day - Effizienzfokus sollte Rückkehr zuhistorischen Margenniveaus ermöglichen (Aktiencheck)
|
|
|
Hamburg (www.aktiencheck.de) - FACC-Aktienanalyse von der Montega AG:
Bastian Brach, Aktienanalyst der Montega AG, rät in einer aktuellen Aktienanalyse die Aktie der FACC AG (ISIN: AT00000FACC2, WKN: A1147K, Ticker-Symbol: 1FC, Wiener Börse-Symbol: FACC) weiterhin zu kaufen.
FACC habe vergangene Woche seinen ersten Kapitalmarkttag seit fünf Jahren abgehalten und am Produktionsstandort in Reichersberg, Österreich, einen Ausblick auf die kommenden Jahre gegeben. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
28.03.25 - 15:06
|
Ginger K. Biesbrock to Receive ACC Presidential Citation Award (Business Wire)
|
|
|
Biesbrock to be recognized for contributions to cardiology during ACC's Annual Scientific Session in Chicago
CHICAGO--(BUSINESS WIRE)--Ginger K. Biesbrock, PA-C, DSc, MPH, FACC, has been awarded the 2025 Presidential Citation Award by the American College of Cardiology (ACC) in honor of her remarkable contributions to the cardiovascular profession. Biesbrock will be recognized for these achievements along with all 2025 Distinguished Award winners during Convocation at the ACC's Annual Scientific Session (ACC.25) taking place March 29 – 31, 2025, in Chicago.
“I am honored to recognize Ginger K. Biesbrock, PA-C, DSc, MPH, FACC, with the Presidential Citation Award,” said ACC president Cathleen Biga, MSN, FACC. “Biesbrock has demonstrated exceptional work that will further the ACC's mission to transform cardiovascular care and improve heart health for all.”
The Presidential Citation Award is awarded to a person whose contributions to the field of cardiology have been truly extraordinary.
As exec...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
